Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Glioblastoma × alectinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 22 Neoplasms 6 Lung Neoplasms 5 Neoplasm Metastasis 3 Breast Neoplasms 3 Thyroid Neoplasms 2 Sarcoma 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasms by Site 2 Lymphoma, Large-Cell, Anaplastic 2 Hematologic Neoplasms 2 Gastrointestinal Neoplasms 2 Colorectal Neoplasms 2 Brain Neoplasms 2 Urinary Bladder Neoplasms 1 Thyroid Cancer, Papillary 1 Thoracic Neoplasms 1 Solid Tumors 1 Salivary Gland Neoplasms 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Rare Tumour 1 Rare Tumor 1 Prostatic Neoplasms 1 Neuroendocrine Tumors 1 Neoplasms, Unknown Primary 1 Neoplasms by Histologic Type 1 Multiple Endocrine Neoplasia Type 2a 1 Melanoma 1

Interventions

Temozolomide 362 Radiotherapy 181 Bevacizumab 142 Radiation 70 Magnetic Resonance Spectroscopy 60 Lomustine 43 pembrolizumab 37 Irinotecan 37 Carmustine 37 Surgical Procedures, Operative 34 Nivolumab 27 Carboplatin 25 Specimen Handling 23 Radiosurgery 23 Erlotinib Hydrochloride 23 Radiotherapy, Intensity-Modulated 20 Chemotherapy, Adjuvant 20 Aminolevulinic Acid 19 Cyclophosphamide 18 Drug Therapy 17 sargramostim 16 O(6)-benzylguanine 14 Radiotherapy, Conformal 13 Granulocyte-Macrophage Colony-Stimulating Factor 13 Everolimus 12 temsirolimus 11 Vorinostat 11 Sunitinib 11 Imatinib Mesylate 11 Etoposide 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03158389 2023-09-28

N²M²

University Hospital Heidelberg

Phase 1/2 Completed

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡